Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: non-randomized clinical trial, pha
Mashayekhi M., Mirzadeh E., Chekini Z., Ahmadi F., Eftekhari-Yazdi P., Vesali S.
Clinical Trial with a reported sample of 3 on Hair & Scalp, published in J Ovarian Res (2021) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- J Ovarian Res (2021)
- Country
- England
- Reported sample size
- 3
- Source database
- PubMed
- PMID
- 33407794
- PMCID
- PMC7786909
- DOI
- 10.1186/s13048-020-00743-3
- NCT
- NCT02603744
- Citations
- 59
Abstract (original English)
Background Premature ovarian failure (POF) is characterized by the loss of ovarian activity before the age of 40 years. Stem cell therapy has the capability to create a regenerative microenvironment and is a proposed treatment for POF-related infertility due to the presence of renewal folliculogenesis and germ cells in the adult ovaries. In this study, we assessed the safety, feasibility, efficacy and dose adjustment of autologous adipose-derived stromal cells (ADSCs) and their ability to improve ovarian function in POF patients. Methods This study was a non-randomized clinical trial, phase I. Nine women with a definitive diagnosis of POF were divided into three groups (n = 3 per group) that received either 5 × 10 6 , 10 × 10 6 , or 15 × 10 6 autologous ADSCs suspension transplanted in the one ovary. Participants were followed-up at 24 h after the transplantation, and at 1 and 2 weeks, and 1, 2, 3, 6, and 12 months after the transplantation. The primary objective was to evaluate the safety of ADSCs transplantation. Secondary objectives included the effects of ADSCs transplantation on the resumption of menstruation, hormones level (Follicle-stimulating hormone (FSH) and anti-Müllerian hormone), ovarian function (Antral follicle count and ovary volume by ultrasonography evaluation) as well as dose escalation. Results Participants had not shown any early-onset possible side effect
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.
Systematic Review with a reported sample of 724 on Hair Loss, Hair Regeneration, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
- n = 724
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
DKK3-CKAP4 signaling drives fibroimmune remodeling and hair follicle miniaturization in androgenetic alopecia
Meta-analysis on Hair Loss, Hair Regeneration, published in Theranostics (2026) — summary generated from the PubMed abstract.
- 2026
Theranostics - Level ASystematic ReviewEurope PMC
Autolougous platelet concentrates in esthetic medicine
Systematic Review on Scar, Skin Aging, Facial Rejuvenation, Hair Regeneration, published in Periodontol 2000 (2025) — summary generated from the PubMed abstract.
- 2025
Periodontol 200016 citations - Level ASystematic ReviewPubMed
The Potency of Adipose-Derived Mesenchymal Stem Cells to Increase Ovarian Function in Primary Ovarian Insufficiency: A Systematic Review of in vivo Studies.
Systematic Review with a reported sample of 5 on Hair & Scalp, published in Gynecol Obstet Invest (2025) — summary generated from the PubMed abstract.
- 2025
- n = 5
Gynecol Obstet Invest - Level ASystematic ReviewPubMed
Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review.
Systematic Review on Hair Regeneration, published in Arch Dermatol Res (2025) — summary generated from the PubMed abstract.
- 2025
Arch Dermatol Res2 citations